Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study

Abstract

The molecular features of mantle cell lymphoma (MCL), including its increased incidence, and complex therapies have not been investigated in detail, particularly in East Asian populations. In this study, we performed targeted panel sequencing (TPS) and whole-exome sequencing (WES) to investigate the genetic alterations in Korean MCL patients. We obtained a total of 53 samples from MCL patients from five Korean university hospitals between 2009 and 2016. We identified the recurrently mutated genes such as SYNE1, ATM, KMT2D, CARD11, ANK2, KMT2C, and TP53, which included some known drivers of MCL. The mutational profiles of our cohort indicated genetic heterogeneity. The significantly enriched pathways were mainly involved in gene expression, cell cycle, and programmed cell death. Multivariate analysis revealed that ANK2 mutations impacted the unfavourable overall survival (hazard ratio [HR] 3.126; P = 0.032). Furthermore, TP53 mutations were related to worse progression-free survival (HR 7.813; P = 0.043). Among the recurrently mutated genes with more than 15.0% frequency, discrepancies were found in only 5 genes from 4 patients, suggesting comparability of the TPS to WES in practical laboratory settings. We provide the unbiased genetic landscape that might contribute to MCL pathogenesis and recurrent genes conferring unfavourable outcomes.

Introduction

Mantle cell lymphoma (MCL) is a mature B-cell non-Hodgkin’s lymphoma (NHL) accounting for 5–7% of all NHLs1. Although MCL is uncommon (0.64/100,000 person-years), there has been a 130.9% rise in its incidence in recent years2. Higher incidence rates have been seen in Caucasians (153.0%), Asians (96.4%), and the elderly (429.2%). Patients with MCL treated with standard therapies have a limited duration of remission, and also show frequent relapses, resulting in a short median overall survival (OS) of 4–5 years3.

Classical MCL expresses the hallmark t(11:14)(q13;q32) chromosomal translocation4. However, the pathogenesis of MCL is complex and the alterations in the genes involved in DNA damage response (ataxia telangiectasia mutated [ATM], checkpoint kinase 2 [CHK2], and TP53) and cell survival signalling pathways (Bruton’s tyrosine kinase [BTK], mammalian target of rapamycin [mTOR], nuclear factor-κB [NF-κB], tumour necrosis factor [TNF], and NOTCH) also play crucial roles5. Moreover, MCL patients exhibit diverse responses to therapies and clinical courses6,7, which has not been completely incorporated by current risk stratification tools. Therefore, it is essential to investigate the genetic landscape of this heterogeneous disease to gain insight into the molecular pathogenesis and to predict the prognosis of MCL patients.

Targeted panel sequencing (TPS) and whole-exome sequencing (WES) have been used as influential tools for discovering the molecular mechanisms of haematologic malignancies8,9,10,11,12. Differences in genomic signatures according to ethnicity have been found in previous MCL studies8,9,10,11,12,13,14,15,16. However, there has been no report of the genetic landscape in Korean or East-Asian MCL patients, which are rarely reported as study populations. Therefore, we aimed to investigate the genetic alterations in MCL patients in Korea using both TPS and WES. Prognostic factors including clinical parameters and gene mutations were also analysed. Furthermore, we conducted a comparative analysis between TPS and WES to determine the ideal prediction tool for MCL patients.

Results

Clinical characteristics

The clinical data of the 50 MCL patients enrolled in this study are summarized in Table 1. The median age was 62.5 years. This cohort predominantly consisted of men (70.0%) and patients with advanced stages (stage IV, 68.0%). The typical t(11;14)(q13;q32) translocation was found in 6 patients (12.0%). One patient had +8,t(8;14)(q24;q32) chromosomal aberration. These chromosomal abnormalities were identified by classical cytogenetics, and not by fluorescence in situ hybridization (FISH). Eleven patients (22.0%) belonged to the high risk group according to mantle cell lymphoma international prognostic index (MIPI). Most patients (82.0%) received rituximab combined chemotherapy such as R-CHOP and R-hyper-CVAD (Supplementary Table S1). The complete and partial remission rates were 44.0% and 22.0%, respectively. The estimated OS rates were 62.1% for 3-year, and 55.2% for 5-year.

Table 1 Clinical data and sample information of patients with mantle cell lymphoma.

MCL mutational landscape

A lymphoma panel was performed on 53 formalin-fixed paraffin-embedded (FFPE) samples derived from MCL patients. Among them, WES was conducted on 16 FFPE samples (4 saliva samples for germline control). The mutational profiles of 53 MCL patients are presented in Fig. 1a, showing genetic heterogeneity. SYNE1, ATM, and KMT2D were the most three common genes having mutations in our MCL cohort (69.8%). We analysed these genes using cBioPortal software (https://www.cbioportal.org/index.do)17. The SYNE1 and KMT2D mutations were frequently found in cutaneous squamous cell carcinoma (cSCC), and have also been reported in previous studies on MCL8,18. The frequencies of SYNE1 (37.7%), and KMT2D mutations (32.1%) in our cohort were higher than those in other MCL cohort studies (6.9% for SYNE18, and 12% to 23% for KMT2D8,9,10,12,18). ATM mutations showed a frequency of 34.0% in our cohort, and previous MCL studies showed that this gene is consistently mutated with a high frequency (15% to 56%8,9,10,11,12,13,14,15,16). ANK2 mutations, detected in cSCC and NHL, were present at a higher frequency (22.6%) in our study than in previous MCL cohort studies12. ANK2 encodes ankyrin-2, which plays a crucial role in cell development12. TP53 mutations have been detected in most studies on genomic alterations in MCL11,12, and this mutation was also reported in our cohort (17.0%). Samples obtained from patients who relapsed showed a higher frequency of TP53 mutation (26.3%) than primary samples (15.4%). However, the difference was not significant (P = 0.463). Among the frequently mutated genes associated with MCL, only SYNE1 (P = 0.020 for Chi-square test, and hazard ratio [HR] 0.167; P = 0.025 for binary logistic regression) was significantly related to primary samples, when compared to relapsed samples. Regarding to mean variant allele frequency, the values of relapsed samples were significantly higher than those of primary samples for SYNE1 (32.4% vs. 60.2%; P = 0.013), ANK2 (35.0% vs. 55.7%; P = 0.042), and TP53 (30.1% vs. 72.4%; P = 0.024) mutations. Ten out of 53 patients harboured KMT2C and MAP1B mutations, which were frequently found in patients with small cell lung cancer19 and NHL 18,20,21,22,23. The frequencies of recurrently mutated genes including ATM, BIRC3, CCND1, KMT2D, NOTCH1, TP53, TRAF2, UBR5, and WHSC1 in other MCL studies compared to those in our study are presented in Supplementary Table S2.

Figure 1
figure1

The mutational spectrum of 53 patients with mantle cell lymphoma. (a) Mutational spectrum with frequencies and clinical data. (b) Genes identified in the lymphoma panel only (left) or by whole-exome sequencing (WES) only (right).

Genes that were detected only in one of the lymphoma panel or WES are presented in Fig. 1b. Among the recurrently mutated genes with more than 15.0% frequency, discrepancies were found in only 5 genes from 4 patients, which showed the comparability of the two methods.

Prognostic risk factors

Univariate and multivariate analyses were performed to investigate the risk factor for the prognosis of MCL patients (Table 2). OS and progression-free survival (PFS) were assigned as independent factors for prognosis, while clinical and genetic mutations were considered as co-variates. The factor that significantly correlated with worse OS was old age (HR 1.086; P = 0.009). High tumour proliferation index (Ki-67 ≥ 30%) and high risk group of MIPI, known as factors of poor prognosis, showed 5.372 and 2.341 of HR for OS, respectively. However, their P-values could not reach the predefined 0.05. The recurrently mutated genes with a frequency of > 15.0% were also included in our prognostic analysis. ANK2 (HR 3.403; P = 0.011) and KMT2C (HR 4.305; P = 0.002) mutations were related to worse OS based on our univariate analysis. In multivariate analysis, ANK2 was determined as an independent predictor (HR 3.126; P = 0.032). Age, and KMT2C showing P-values less than 0.05 in univariate analysis were co-variates for the multivariate analysis for ANK2 gene. The patients with ANK2 mutations showed significantly shorter median survival time (26.3 months) than those without (124.9 months) (P = 0.010) according to survival analysis.

Table 2 Univariate and multivariate analyses for overall survival and progression-free survival in mantle cell lymphoma patients.

Regarding to PFS, TP53 (HR 9.300; P = 0.004), KMT2C (HR 6.116; P = 0.025), and MAP1B (HR 15.392; P = 0.004) were associated based on univariate analysis. Among them, TP53 was a significant predictor of PFS according to multivariate analysis (HR 7.813; P = 0.043). Patients with TP53 mutations had significantly shorter median PFS time (8.0 months) than those without (47.5 months) (P = 0.004). The survival curves calculated based on patient age and the presence of mutated genes using the Kaplan–Meier method are illustrated in Fig. 2a-f.

Figure 2
figure2

Kaplan–Meier curves for overall survival and progression-free survival of patients with mantle cell lymphoma. Kaplan–Meier curves of (a) age classes for overall survival, (b) ANK2 mutation for overall survival, (c) KMT2C mutation for overall survival, (d) KMT2C mutation for progression-free survival, (e) MAP1B mutation for progression-free survival, and (f) TP53 mutation for progression-free survival. The presented P-values were calculated using the log-rank test.

Pathways affected by mutations

We conducted functional enrichment analysis of the mutated genes in our MCL cohort (Fig. 3a). The specific names of the 25 most significant pathways, which mainly consisted of pathways related to gene expression, cell cycle, and programmed cell death, are presented in Supplementary Table S3. TP53, ATM, and KMT2D are mainly involved in gene expression and cell cycle pathways such as regulation of TP53 expression and auto-degradation of the E3 ubiquitin ligase COP1. Meanwhile, ANK2 was found to be involved in pathways related to developmental biology and vesicle-mediated transport. The focused locations of amino acid changes on ANK2 and TP53 mutations in this cohort are illustrated in Fig. 3b and c, respectively. The changes of p.D3340G and p.3774 M were presented recurrently in MCL patients with ANK2 mutations.

Figure 3
figure3

Pathway analysis and amino acid changes resulting from the determined ANK2 and TP53 mutations. (a) Pathway analysis of mutational genes with a frequency of more than 15.0% in mantle cell lymphoma samples. (b) The location of amino acid changes resulting from ANK2 and (c) TP53 mutations.

Discussion

To the best of our knowledge, this is the first study reporting the TPS and WES for comprehensive genomic investigation of MCL patients in Korea. We have shown the heterogeneous spectrum of the genetic mutations of this form of lymphoma. We have also discovered several molecular mechanisms contributing to its pathogenesis. Furthermore, we analysed the impact of recurrent ANK2 and TP53 mutations for clinical prognosis including OS and PFS. We also investigated the comparison between TPS and WES to suggest more appropriate laboratory settings.

Among the commonly mutated genes in our study, SYNE1, ATM, KMT2D, CARD11, ANK2, ROBO2, CRYBG3, KMT2C, TP53, and DLC1 were previously identified in MCL studies1,8,11,12,18. The mutational profiles shown in our cohort including the detected genes, variations, and frequencies showed substantial genetic heterogeneity, consistent with previous studies. Mutations in CDH23, ABCA7, LRP1B, MAP1B, MKI67, TCF3, and ABCA13, rarely reported in previous MCL studies, presented more than 15.0% in our study. Ethnic variations, specimen status, the applied reagents and equipment, sequence depth, and the coverage of the target genes may have influenced these differences.

In this study, we most commonly identified SYNE1 mutations (37.7%), which were detected at a rate of 6.9% in a previous MCL cohort study8. The SYNE1 was listed as one of the recurrently mutated genes in MCL and diffuse large B-cell lymphoma literatures1. Furthermore, a study for frequent mutation of histone modifying genes in NHL also reported SYNE1 mutation24. This gene, located on 6q25.1–25.2, encodes nesprin-1, which is involved in communication between the nuclear lamina and the cytoskeleton25. Nesprin-1 is critical for nuclear positioning and anchorage. This protein has been correlated in dilated cardiomyopathy26. In cancers, SYNE1 showed medium and high expression in lymphoma patients and likely drive transformation of lymphoma27. Regarding to the relapsed status, the frequency of SYNE1 mutations was lower than that of primary samples. However, the mean allele frequency of SYNE1 mutations was significantly increased in relapsed samples compared to initial samples. In a previous study, SYNE1 mutations were reported as relapse-associated mutations in paediatric acute lymphoblastic leukaemia28. A minor clone with a SYNE1 mutation was identified at the first relapse, and it became dominant at the second relapse. Moreover, Shah et al.29 suggested a plausible role of CD44v-SYNE1-miRNA34a axis as biomarkers to diagnose oral cancer at an early stage and predict the early onset of metastasis. Although the underlying mechanism of SYNE1 gene is unraveled and the relation to tumourigenesis is controversial, SYNE1 mutation might be used at least as a biomarker for relapsed status, considering the mean allele frequencies of our cohort. Further investigating these results on a larger sample set is necessary.

The second most frequently detected mutation found in our study was in ATM (34.0%), which has been a previously identified MCL driver. ATM mutations have been found in 41.4% of Western patients and 37.5% of Chinese patients8,11. The ATM mutations included nonsense and frameshift mutations, similar to those observed in previous MCL studies. We found that various mutated forms of ATM were involved in gene expression and cell cycle pathways. In particular, this gene encodes a tumour suppressor involved in DNA damage response30. Additionally, ATM mutations are related to the inactivation of the ARF-TP53 tumour suppressor pathway31. These forms have also been reported in different subtypes of lymphoid malignancies32,33.

KMT2D showed a mutation rate of 32.1% in this study compared to 12–23% in previously reported MCL studies18. The epigenetic modifier, KMT2D, has been identified as an early MCL driver34. We also frequently detected KMT2D nonsense and frameshift mutations in our cohort, supporting its contribution to lymphomagenesis. Somatic mutations leading to inactivation of the KMT2D methyltransferase perturb germinal center B cell development and promote lymphomagenesis by remodeling the epigenetic landscape of the cancer precursor cells35.

ANK2 and TP53 were significantly related to OS (HR 3.126) and PFS (HR 7.813), respectively. A higher mutation frequency (22.6%) was observed in ANK2 encoding ankyrin-212,36. This protein is crucial for the localization and membrane stabilization of ion transporters and ion channels, especially in cardiomyocytes. Therefore, ankyrin mutations are generally associated with cardiac arrhythmia and sudden cardiac death37. In terms of malignancies, the silencing of ANK2 expression reduced the growth and invasion of pancreatic cancer cells, indicating its potential as a target for therapy38. Further, ANK2 expression levels had a significant correlation with the clinical outcome in gastrointestinal cancer39. Regarding to MCL, 5.6% (3/56) of ANK2 mutations were identified from the lymph node samples of Caucasian male patients in a previous study12. The described results analyzed by PolyPhen-2 included damaging (1.0), and possibly damaging (0.7) predictions. Similar to this study, our cohort also revealed damaging and possibly damaging predictions based on the scores analyzed by SIFT (0.001 to 0.034) and PolyPhen-2 (0.627 to 0.999). ANK2 encodes Ankyrin-2, which belongs to a family of cytoskeletal proteins mediating linkage of integral membrane proteins with the spectrin-actin based skeleton. Ankyrin-2 is involved in pathways associated with a variety of biological activities such as cell motility, activation, proliferation, contact, and the maintenance of specialized membrane domains36. Ankyrin repeat domain, a highly conserved membrane-binding domain shared by ankyrin encoding genes, is seemed to be directly associated with the binding of ankyrins to various types of proteins. In particular, binding to CD44, which is a transmembrane glycoprotein mediating lots of important activities of tumour cells, has been reported. This interaction was responsible for a more severe malignant phenotype in cancer cells40. Regarding to cancers, ankyrins influence on signal transduction, cell adhesion, membrane transport, cell growth, migration and metastasis of cancer cells38,40. In terms of relapse, some breast cancer samples in the poor prognosis group revealed significantly higher ANK2 expression, indicating that ANK2 may be related to personalized relapse mechanism41. Cao et al.42 demonstrated that signaling pathways including ANK2 were modulated by miR-647 and mediated the proliferation and metastasis of gastric cancer cells. In our study, the mean allele frequencies of ANK2 mutations were significantly increased in relapsed samples, suggesting its oncogenic function in lymphomagenesis. However, further investigations are required with large sample sizes to validate the impact of ANK2 mutations in MCL patients.

With respect to PFS, we found that TP53 was found to be an efficient predictor based on our multivariate analysis. Several studies into MCL have demonstrated the association of TP53 mutations with poor clinical outcomes11,43. TP53 alterations were previously associated with a poor prognosis in MCL patients treated with standard treatment modalities44,45. A recent study suggested that allogeneic hematopoietic cell transplantation may be a beneficial treatment option for patients with TP53 mutations46. For the younger MCL patients receiving cytarabine-containing chemotherapy and autologous stem cell transplantation, Ferrero et al.9 developed the MIPI-genetic index (MIPI-g), which is a prognostic model integrating MIPI-c prognostic index with genetic data (TP53, and KMT2D mutations). Despite being a different study population, we applied the MIPI-g to our cohort and found that the high risk patients were significantly related to worse PFS (HR 20.601; P = 0.025) (Supplementary Fig. S1). Based on these findings, we propose that TP53 should be routinely assessed as a molecular marker to determine the prognosis, as well as to guide treatment decisions. In respect of relapse, a study on younger MCL patients showing 11% of mutation frequency and 26.9% of mean allele frequency for TP53 mutations demonstrated the independent prognostic impact of TP53 mutations on time to relapse47.

To the best of our knowledge, there has been no previous report investigating TPS and WES concurrently using the same lymphoma samples. We compared TPS and WES for the first time in this study to improve the practical laboratory settings for the MCL patients. Among the recurrently mutated genes with more than 15.0% frequency, we found discrepancies in only 5 genes (TP53, CARD11, SYNE1, MKI67, and ANK2) from 4 patients, which shows the comparability of these two settings. However, utilized platforms, the read depth and coverage of the target (365.9X for TPS, and 144.0X for WES) may influence on these results. A previous comparison study, which applied TPS and WES to patients with inherited retinal dystrophy, demonstrated that TPS including 291 genes could be used as a first-tier test48.

This study had several limitations. The study population was relatively small, reflecting the uncommon incidence of MCL in Korea. Moreover, the samples with unknown state for disease course lessened the available analysis, and statistical power. Further study with a much larger number of patients might enable subgroup analysis and demonstrate stronger statistical relationship between genetic mutations and prognosis. Additional confirmation using Sanger sequencing could not be conducted for mutations with low read depth due to lack of remaining DNA samples. Performing this analysis would serve to rule out false positives, and should therefore be performed in future studies to confirm the current results. In addition, fresh samples rather than FFPE specimens, which were available in this multicenter study, might provide better quality of sequencing data.

In conclusion, we performed TPS and WES for the comprehensive genomic investigation of MCL patients using samples from five university hospitals in Korea, a racially homogeneous country of East Asia for the first time. This study has revealed the heterogeneous spectrum in the genetic alterations of MCL. We not only identified several mutated genes such as SYNE1, ATM, and KMT2D, which contribute to pathogenesis, but also showed that recurrent ANK2 and TP53 mutations had negative impacts on the OS and PFS, respectively. In particular, our study suggests that TPS may be comparable to WES in practical laboratory settings. In the future, the sequencing of these identified genes will benefit MCL patients by improving the prognosis and the choice of therapeutic interventions.

Methods

Patients and sample preparation

A total of 53 samples were collected from MCL patients from five university hospitals in Korea between March 2009 and October 2016. The FFPE specimens that were stored at the Kosin University Gospel Hospital (n = 26), Asan Medical center (n = 11), Ulsan University Hospital (n = 8), Gangnam Severance Hospital (n = 6), and Pusan National University Hospital (n = 2) were obtained. The MCL samples were confirmed after a diagnosis was made based on the criteria established by the World Health Organization classification with mantle zone B cell phenotypes49. As the chromosomal aberrations were identified by classical cytogenetics, it might have been affected by laboratory settings such as sample state, resolution of the image, and interpretation, additional pathological confirmation by pathologists from the Kosin University Gospel Hospital was conducted. Further, pathologists also confirmed that all samples were at least positive for cyclin D1. The tested samples were lymph nodes containing more than 80% tumour cells, as confirmed by the pathologists.

Records of medical visits, demographic information, and clinical data were collected and reviewed for all patients diagnosed with MCL. The sample selection procedure used for evaluating the genetic and prognostic parameters is shown in Supplementary Fig. S2. This study was approved by the independent Institutional Review Board of Kosin University Gospel Hospital (KUGH 2017-02-011) and conducted in accordance with the Declaration of Helsinki. We obtained informed consents from all the MCL patients and personal information was protected and kept anonymous.

TPS and WES

A total of 588 genes known to be related to lymphoma were included in our gene panel; the genes are listed in Supplementary Table S4. The targeted lymphoma panel consisted of frequently mutated genes in the previously reported 26 studies of lymphoma including particularly MCL1,8,10,11,12,18,21,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68. The mutated genes in lymphoma samples deposited in databases such as Catalogue of Somatic Mutations in Cancer (COSMIC), ClinVar, and Human Gene Mutation Database (HGMD) were also selected for broader range of targets of TPS. Briefly, the sequencing data were analysed as follows. Genomic DNA was extracted from 55 FFPE tissue samples using a deparaffinization solution and the QIAamp Blood DNA mini kit (Qiagen, Hilden, Germany). We constructed genomic DNA libraries and captured the custom lymphoma panel using the Library Preparation Kit (Celemics, Seoul, Korea). The pooled libraries were sequenced using a NextSeq sequencer (Illumina, San Diego, CA, USA) and the NextSeq Reagent Kit v2 (500 cycles). The average read depth of 53 samples was 365.9X. The read depths and coverages per samples are presented in Supplementary Table S5.

The Agilent SureSelect Human All Exon platform (Agilent Technologies Inc., Santa Clara, CA, USA) was used for WES to capture the target DNA samples and generate standard exome libraries. The entire exome regions for 12 FFPE tumour tissues and 4 saliva samples from 12 MCL patients were sequenced using the HiSeq 2500 platform with a paired-end read protocol (Illumina). The saliva samples were prepared using AccuSaliva collection kits (AccuGene Inc., Incheon, Korea) for normal control. All tumour and normal samples were sequenced with an average read depth of 144.0X. The read depths and coverages per samples are shown in Supplementary Table S6.

The filtered reads were aligned to the reference assembly of hg19 reference sequence using BWA software (version 0.7.5). Indel realignment and base quality score recalibration were performed using MuTect2 in GATK software (version 3.7) to identify somatic single-nucleotide variants (SNVs) based on the Catalogue of Somatic Mutations in Cancer (COSMIC) database69. Short indels were identified using VarScan (version 2.3). The mutations (SNVs and indels) found in each sample were annotated using ANNOVAR software. The quality of the mutations in the sequenced BAM files were manually reviewed using Integrated Genomics Viewer (Broad Institute., Cambridge, MA, USA) to filter out false positives. The mean numbers of mutations detected by TPS and WES were 9184.9, and 1023.5, respectively. Among the mutations identified by TPS and WES, the numbers of filtered and reported mutations were 698 for TPS, and 291 for WES. The threshold for total read depth of the reported mutations was 10X. All single nucleotide polymorphisms with a frequency of > 1% in the Korean Variant Archive, 1000 Genomes Project, esp6500 database, and EXAC database were removed. We found no significant differences between the mutations that were adjusted with the variations of normal control and those without. The variants that were determined to be pathogenic or likely pathogenic based on the American College of Medical Genetics and Genomics, COSMIC, and the Association for Molecular Pathology classification70 were considered causative mutations for MCL. Subsequently, genotype–phenotype correlations were discussed by clinical pathologists and haemato-oncologists. The significant mutational profiles of 53 MCL patients including variant allele frequency, read depth, and SIFT and PolyPhen-2 predictions are presented in Supplementary Table S7. The presented variant of allele frequency was more than 5%.

Pathway and survival statistical analysis

Functional enrichment analysis of the recurrently mutated genes was performed using the Reactome tool71. Descriptive statistics were used for the characteristics and sample information of the MCL patients. Multivariate Cox proportional-hazards regression models were used to examine the factors correlated with OS or PFS. OS was determined from the date of diagnosis to the date of death from any causes (event), or the last follow up (censoring). PFS was calculated from the date of treatment to the date of disease progression (event), death from any causes (event), or the last follow up (censoring)72 for the MCL patients including primary and relapsed patients in our cohort as post relapse survival might lead to biased estimates based on the report of García-Albéniz et al.73. The Kaplan–Meier method with log-rank test was used to estimate the survival curves. Statistical analyses were performed using RStudio statistical software (version 3.6.0; R Foundation for Statistical Computing, Vienna, Austria) and SPSS (version 24.0; IBM, Armonk, NY, USA). Values of P < 0.05 were considered statistically significant.

Data availability

All data generated or analyzed during this study are included in this published article (Tables, Figures, and Supplementary information) and available from the corresponding author on reasonable request. The data discussed in this study have been deposited in NCBI’s Sequence Read Archive and are accessible through accession number SRR10572983.

References

  1. 1.

    Wu, C. et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget7, 38180–38190. https://doi.org/10.18632/oncotarget.9500 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Aschebrook-Kilfoy, B., Caces, D. B., Ollberding, N. J., Smith, S. M. & Chiu, B. C. An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma54, 1677–1683. https://doi.org/10.3109/10428194.2012.760041 (2013).

    Article  PubMed  Google Scholar 

  3. 3.

    Kang, B. W. et al. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the Consortium for Improving Survival of Lymphoma. Blood Res.49, 15–21. https://doi.org/10.5045/br.2014.49.1.15 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Perez-Galan, P., Dreyling, M. & Wiestner, A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood117, 26–38. https://doi.org/10.1182/blood-2010-04-189977 (2011).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Jares, P. & Campo, E. Advances in the understanding of mantle cell lymphoma. Br. J. Haematol.142, 149–165. https://doi.org/10.1111/j.1365-2141.2008.07124.x (2008).

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Choi, Y. J. et al. Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma. Sci. Rep.9, 7193. https://doi.org/10.1038/s41598-019-43760-z (2019).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Ratnasingam, S. et al. Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. Sci. Rep.9, 13544. https://doi.org/10.1038/s41598-019-49776-9 (2019).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Bea, S. et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc. Natl. Acad. Sci. USA110, 18250–18255. https://doi.org/10.1073/pnas.1314608110 (2013).

    ADS  Article  PubMed  Google Scholar 

  9. 9.

    Ferrero, S. et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica https://doi.org/10.3324/haematol.2018.214056 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Rossi, D., Ciardullo, C. & Gaidano, G. Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies. Semin. Cancer Biol.23, 422–430. https://doi.org/10.1016/j.semcancer.2013.04.002 (2013).

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Yang, P. et al. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther.25, 129–140. https://doi.org/10.1038/s41417-018-0022-5 (2018).

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Zhang, J. et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood123, 2988–2996. https://doi.org/10.1182/blood-2013-07-517177 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Greiner, T. C. et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc. Natl. Acad. Sci. USA103, 2352–2357. https://doi.org/10.1073/pnas.0510441103 (2006).

    ADS  CAS  Article  PubMed  Google Scholar 

  14. 14.

    Kridel, R. et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood119, 1963–1971. https://doi.org/10.1182/blood-2011-11-391474 (2012).

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Meissner, B. et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood121, 3161–3164. https://doi.org/10.1182/blood-2013-01-478834 (2013).

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Rahal, R. et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med20, 87–92. https://doi.org/10.1038/nm.3435 (2014).

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal6, l1. https://doi.org/10.1126/scisignal.2004088 (2013).

    CAS  Article  Google Scholar 

  18. 18.

    Rosenquist, R., Bea, S., Du, M. Q., Nadel, B. & Pan-Hammarstrom, Q. Genetic landscape and deregulated pathways in B-cell lymphoid malignancies. J. Intern. Med.282, 371–394. https://doi.org/10.1111/joim.12633 (2017).

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Gardner, E. E. et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 Axis. Cancer Cell31, 286–299. https://doi.org/10.1016/j.ccell.2017.01.006 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med24, 679–690. https://doi.org/10.1038/s41591-018-0016-8 (2018).

    MathSciNet  CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Morin, R. D. & Gascoyne, R. D. Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing. Semin. Hematol.50, 303–313. https://doi.org/10.1053/j.seminhematol.2013.09.004 (2013).

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Reddy, A. et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell171, 481-494 e415. https://doi.org/10.1016/j.cell.2017.09.027 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Roschewski, M. et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol.16, 541–549. https://doi.org/10.1016/S1470-2045(15)70106-3 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Morin, R. D. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature476, 298–303. https://doi.org/10.1038/nature10351 (2011).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Taranum, S. et al. Cytoskeletal interactions at the nuclear envelope mediated by nesprins. Int. J. Cell Biol.2012, 736524. https://doi.org/10.1155/2012/736524 (2012).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Zhou, C. et al. Novel nesprin-1 mutations associated with dilated cardiomyopathy cause nuclear envelope disruption and defects in myogenesis. Hum. Mol. Genet.26, 2258–2276. https://doi.org/10.1093/hmg/ddx116 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Bouska, A. et al. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia31, 83–91. https://doi.org/10.1038/leu.2016.175 (2017).

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Lindqvist, C. M. et al. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes. Oncotarget7, 64071–64088. https://doi.org/10.18632/oncotarget.11773 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Shah, K., Patel, S., Modi, B., Shah, F. & Rawal, R. Uncovering the potential of CD44v/SYNE1/miR34a axis in salivary fluids of oral cancer patients. J. Oral Pathol. Med.47, 345–352. https://doi.org/10.1111/jop.12678 (2018).

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Klener, P. Advances in molecular biology and targeted therapy of mantle cell lymphoma. Int. J. Mol. Sci. https://doi.org/10.3390/ijms20184417 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Gronbaek, K. et al. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. Blood100, 1430–1437. https://doi.org/10.1182/blood-2002-02-0382 (2002).

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    de Miranda, N. F. et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. Blood124, 2544–2553. https://doi.org/10.1182/blood-2013-12-546309 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Rossi, D. et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood119, 2854–2862. https://doi.org/10.1182/blood-2011-12-395673 (2012).

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Jiang, Y. et al. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol.15, 432. https://doi.org/10.1186/s13059-014-0432-0 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Zhang, J. et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat. Med.21, 1190–1198. https://doi.org/10.1038/nm.3940 (2015).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Cunha, S. R. & Mohler, P. J. Ankyrin protein networks in membrane formation and stabilization. J. Cell Mol. Med.13, 4364–4376. https://doi.org/10.1111/j.1582-4934.2009.00943.x (2009).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Mohler, P. J. et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature421, 634–639. https://doi.org/10.1038/nature01335 (2003).

    ADS  CAS  Article  PubMed  Google Scholar 

  38. 38.

    Chen, Y., Lohr, M. & Jesnowski, R. Inhibition of ankyrin-B expression reduces growth and invasion of human pancreatic ductal adenocarcinoma. Pancreatology10, 586–596. https://doi.org/10.1159/000308821 (2010).

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Hu, W., Yang, Y., Ge, W. & Zheng, S. Deciphering molecular properties of hypermutated gastrointestinal cancer. J. Cell Mol. Med.23, 370–379. https://doi.org/10.1111/jcmm.13941 (2019).

    CAS  Article  PubMed  Google Scholar 

  40. 40.

    Zhu, D. & Bourguignon, L. Y. Interaction between CD44 and the repeat domain of ankyrin promotes hyaluronic acid-mediated ovarian tumor cell migration. J. Cell. Physiol.183, 182–195. https://doi.org/10.1002/(sici)1097-4652(200005)183:2<182::Aid-jcp5>3.0.Co;2-o (2000).

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Chen, X. et al. Identification of breast cancer recurrence risk factors based on functional pathways in tumor and normal tissues. Oncotarget8, 20679–20694. https://doi.org/10.18632/oncotarget.11557 (2017).

    Article  PubMed  Google Scholar 

  42. 42.

    Cao, W. et al. Role of miR-647 in human gastric cancer suppression. Oncol. Rep.37, 1401–1411. https://doi.org/10.3892/or.2017.5383 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Nordstrom, L. et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a Nordic Lymphoma Group study. Br. J. Haematol.166, 98–108. https://doi.org/10.1111/bjh.12854 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Delfau-Larue, M. H. et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood126, 604–611. https://doi.org/10.1182/blood-2015-02-628792 (2015).

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Eskelund, C. W. et al. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica103, e541–e543. https://doi.org/10.3324/haematol.2018.194399 (2018).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Lin, R. J. et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br. J. Haematol.184, 1006–1010. https://doi.org/10.1111/bjh.15721 (2019).

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Eskelund, C. W. et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood130, 1903–1910. https://doi.org/10.1182/blood-2017-04-779736 (2017).

    CAS  Article  PubMed  Google Scholar 

  48. 48.

    Wang, L. et al. Application of whole exome and targeted panel sequencing in the clinical molecular diagnosis of 319 Chinese Families with inherited retinal dystrophy and comparison study. Genes (Basel) https://doi.org/10.3390/genes9070360 (2018).

    Article  PubMed Central  Google Scholar 

  49. 49.

    Gao, J., Peterson, L., Nelson, B., Goolsby, C. & Chen, Y. H. Immunophenotypic variations in mantle cell lymphoma. Am. J. Clin. Pathol.132, 699–706. https://doi.org/10.1309/AJCPV8LN5ENMZOVY (2009).

    Article  PubMed  Google Scholar 

  50. 50.

    Ahmed, M., Zhang, L., Nomie, K., Lam, L. & Wang, M. Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget7, 58638–58648. https://doi.org/10.18632/oncotarget.10716 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Braggio, E., Egan, J. B., Fonseca, R. & Stewart, A. K. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J.3, e127. https://doi.org/10.1038/bcj.2013.26 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Blenk, S. et al. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis. BMC Cancer8, 106. https://doi.org/10.1186/1471-2407-8-106 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Chiron, D. et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov.4, 1022–1035. https://doi.org/10.1158/2159-8290.CD-14-0098 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Inamdar, A. A. et al. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. Oncotarget https://doi.org/10.18632/oncotarget.8961 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  55. 55.

    Reis-Sobreiro, M. et al. Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J.3, e118. https://doi.org/10.1038/bcj.2013.15 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Sanchez-Tillo, E. et al. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ.21, 247–257. https://doi.org/10.1038/cdd.2013.123 (2014).

    CAS  Article  PubMed  Google Scholar 

  57. 57.

    Zhong, W. et al. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients. Oncotarget8, 49757–49772. https://doi.org/10.18632/oncotarget.17693 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Desai, S. et al. PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol. Cancer Res.8, 907–918. https://doi.org/10.1158/1541-7786.MCR-10-0131 (2010).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Ghobrial, I. M. et al. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood105, 3722–3730. https://doi.org/10.1182/blood-2004-10-3999 (2005).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Kurtova, A. V., Tamayo, A. T., Ford, R. J. & Burger, J. A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood113, 4604–4613. https://doi.org/10.1182/blood-2008-10-185827 (2009).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Liu, H. et al. Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma. J. Exp. Med.205, 1843–1858. https://doi.org/10.1084/jem.20072102 (2008).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Martin-Moreno, A. M. et al. CSF1R protein expression in reactive lymphoid tissues and lymphoma: its relevance in classical hodgkin lymphoma. PLoS ONE10, e0125203. https://doi.org/10.1371/journal.pone.0125203 (2015).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Morimoto, K. et al. LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF-kappaB activation. Sci. Rep.6, 25738. https://doi.org/10.1038/srep25738 (2016).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Pathak, P., Li, Y., Gray, B. A., May, W. S. Jr. & Markham, M. J. Synchronous occurrence of chronic myeloid leukemia and mantle cell lymphoma. Case Rep. Hematol.2017, 7815095. https://doi.org/10.1155/2017/7815095 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Rinaldi, A. et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol.132, 303–316. https://doi.org/10.1111/j.1365-2141.2005.05883.x (2006).

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Sayan, A. E. Tumour-promoting role of EMT-inducing transcription factor ZEB1 in mantle cell lymphoma. Cell Death Differ.21, 194–195. https://doi.org/10.1038/cdd.2013.178 (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Smith, S. M. Targeting mTOR in mantle cell lymphoma: current and future directions. Best Pract. Res. Clin. Haematol.25, 175–183. https://doi.org/10.1016/j.beha.2012.04.008 (2012).

    CAS  Article  PubMed  Google Scholar 

  68. 68.

    Ye, H. et al. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. Am. J. Pathol.157, 1147–1154. https://doi.org/10.1016/s0002-9440(10)64630-5 (2000).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol.31, 213. https://doi.org/10.1038/nbt.2514 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  70. 70.

    https://www.nature.com/articles/nbt.2514#supplementary-information (2013).

  71. 71.

    Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn19, 4–23. https://doi.org/10.1016/j.jmoldx.2016.10.002 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Fabregat, A. et al. Reactome pathway analysis: a high-performance in-memory approach. BMC Bioinform.18, 142. https://doi.org/10.1186/s12859-017-1559-2 (2017).

    CAS  Article  Google Scholar 

  73. 73.

    Cheson, B. D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol.25, 579–586. https://doi.org/10.1200/JCO.2006.09.2403 (2007).

    Article  PubMed  Google Scholar 

  74. 74.

    Garcia-Albeniz, X., Maurel, J. & Hernan, M. A. Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials. Int. J. Cancer136, 2444–2447. https://doi.org/10.1002/ijc.29278 (2015).

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

S.J., Y.J.P., and H.S.L. designed the study and were major contributors in writing the manuscript. W.Y., S.T.L., and J.R.C. designed, performed, and analysed the targeted lymphoma panel. E.H.C., E.G.J., and J.L. performed WES. C.S., J.C.J., H.J.C., H.K.C., Y.J.C., H.K., and D.J.K. contributed to the collection and the confirmation of MCL samples and reviewed patient data. J.Y.J., M.J.P., W.S., Y.P., and Y.S.L. analysed the sequencing data and determined the genotype–phenotype correlations. All authors reviewed the manuscript.

Corresponding author

Correspondence to Ho Sup Lee.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Jeong, S., Park, Y.J., Yun, W. et al. Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study. Sci Rep 10, 13359 (2020). https://doi.org/10.1038/s41598-020-70310-9

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing